Completed PHASE2 INTERVENTIONAL 6-arm NCT05103332

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2)

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication

Sponsor: Alnylam Pharmaceuticals

Conditions Hypertension

Interventions Amlodipine Indapamide Olmesartan Placebo Zilebesiran

Updated 33 times since 2021 Last updated: Oct 17, 2025 Started: Nov 5, 2021 Primary completion: Dec 11, 2023 Completion: Sep 13, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05103332, this PHASE2 trial focuses on Hypertension and remains completed. Sponsored by Alnylam Pharmaceuticals, it has been updated 33 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

33 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
Aug 2025 — Sep 2025 [monthly]

Completed PHASE2
Nov 2024 — Aug 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Oct 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 28 earlier versions

Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
May 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE2
Apr 2024 — May 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2024 — Mar 2024 [monthly]

Active Not Recruiting PHASE2
Dec 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE2
Sep 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE2
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alnylam Pharmaceuticals

Data source: Alnylam Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Acworth, United States , Amarillo, United States , Bell Gardens, United States , Bellshill, United Kingdom , Beverly Hills, United States , Brampton, Canada , Burke, United States , Canoga Park, United States , Canton, United States , Carlsbad, United States and 89 more locations